SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (364)11/18/1999 10:36:00 AM
From: biowa   of 666
 
V1

<<Can someone help explaining why the abstract says that there was dosemitry used. I thought Zev didn't use dosemitry.>>

They have another abstract showing that Zevalin biodistribution and organ dosing isn't affected by prior treatment w/ Rituxan. They appear to be doing dosimetry in the clinical studies to demonstrate that its unnecessary in clinical application; that a standard dose (0.4mCi/kg) is appropriate. At least that's what it looks like to me.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News